Document is current
Any future updates will be listed below
-
Authors
Rodríguez-Fernández, Blanca
Vilor-Tejedor, Natalia http://orcid.org/0000-0003-4935-6721
Arenaza-Urquijo, Eider M.
Sánchez-Benavides, Gonzalo
Suárez-Calvet, Marc
Operto, Grégory
Minguillón, Carolina
Fauria, Karine
Kollmorgen, Gwendlyn
Suridjan, Ivonne
de Moura, Manuel Castro
Piñeyro, David
Esteller, Manel
Blennow, Kaj
Zetterberg, Henrik
De Vivo, Immaculata
Molinuevo, José Luis
Navarro, Arcadi
Gispert, Juan Domingo
Sala-Vila, Aleix
Crous-Bou, Marta http://orcid.org/0000-0003-1493-4288
,
Akinci, Müge
Beteta, Annabella
Brugulat-Serrat, Anna
Cacciaglia, Raffaele
Cañas, Alba
Cumplido, Irene
Deulofeu, Carme
Dominguez, Ruth
Emilio, Maria
Falcon, Carles
Fuentes, Sherezade
Grau-Rivera, Oriol
González-de-Echávarri, José M.
Hernandez, Laura
Genius, Patricia
Huesa, Gema
Huguet, Jordi
Palacios, Eva M.
Marne, Paula
Menchón, Tania
Milà-Alomà, Marta
Peña-Gomez, Cleofé
Polo, Albina
Pradas, Sandra
Salvadó, Gemma
Shekari, Mahnaz
Soteras, Anna
Stankeviciute, Laura
Vilanova, Marc
- License Information
-
More Information
Article History
Received: 2 May 2022
Accepted: 16 October 2022
First Online: 7 November 2022
Declarations
:
: The study was conducted in accordance with the directives of the Spanish Law 14/2007, of 3rd of July, on Biomedical Research (Ley 14/2007 de Investigación Biomédica). The ALFA and ALFA+ study protocols have been approved by the Independent Ethics Committee “Parc de Salut Mar,” Barcelona and registered at ClinicalTrials.gov (ALFA Identifier: NCT01835717; ALFA+ Identifier: NCT02485730). All participants accepted the study procedures by signing an informed consent form.
: Not applicable.
: GK is a full-time employee of Roche Diagnostics GmbH. IS is a full-time employee and shareholder of Roche Diagnostics International Ltd. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, and CogRx; has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant, at advisory boards, or data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. JLM is currently a full-time employee of Lundbeck and priorly has served as a consultant or at advisory boards for the following for-profit companies, or has given lectures in symposia sponsored by the following for-profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, and ProMIS Neurosciences. MSC has served as a consultant and at advisory boards for Roche Diagnostics International Ltd and has given lectures in symposia sponsored by Roche Diagnostics, S.L.U, and Roche Farma, S.A. The other co-authors declare that they have no competing interests.
